argenx SE – (NASDAQ:ARGX) – Investment analysts at Wedbush dropped their FY2021 earnings per share (EPS) estimates for shares of argenx in a report issued on Monday, November 5th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of ($7.33) per share for the year, down from their prior forecast of ($6.63). Wedbush currently has a “Outperform” rating and a $125.00 target price on the stock. Wedbush also issued estimates for argenx’s FY2022 earnings at $3.21 EPS.
ARGX has been the subject of a number of other reports. Stifel Nicolaus restated a “buy” rating on shares of argenx in a report on Thursday, November 1st. SunTrust Banks boosted their price objective on shares of argenx to $132.00 and gave the stock an “in-line” rating in a report on Tuesday, September 18th. JMP Securities boosted their target price on shares of argenx to $150.00 and gave the company an “outperform” rating in a research note on Monday, September 17th. Evercore ISI assumed coverage on shares of argenx in a research note on Monday, October 15th. They set an “outperform” rating and a $110.00 target price for the company. Finally, Piper Jaffray Companies reiterated an “overweight” rating and set a $154.00 target price on shares of argenx in a research note on Monday, September 17th. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $131.00.
A number of institutional investors and hedge funds have recently made changes to their positions in ARGX. Atria Investments LLC purchased a new stake in argenx during the 2nd quarter valued at $213,000. Fred Alger Management Inc. raised its stake in argenx by 50.0% during the 2nd quarter. Fred Alger Management Inc. now owns 3,000 shares of the company’s stock valued at $249,000 after buying an additional 1,000 shares during the last quarter. Clear Harbor Asset Management LLC purchased a new stake in argenx during the 3rd quarter valued at $326,000. Dimensional Fund Advisors LP purchased a new stake in argenx during the 1st quarter valued at $498,000. Finally, Northern Trust Corp purchased a new stake in argenx during the 1st quarter valued at $896,000. Institutional investors and hedge funds own 56.10% of the company’s stock.
argenx Company Profile
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Recommended Story: What is a Tariff?
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.